Eisai (OTCMKTS:ESALY) has announced that it has completed the construction of a new research building dedicated to the formulation of injectable drugs at the Kawashima Industrial Park located in Gifu Prefecture, Japan.
The Eisai Medicine Innovation Technology Solutions (EMITS) facility will serve as Eisai’s global headquarters for formulation and research.
Traditionally focusing on small molecules, Eisai has ramped up its focus on drug discovery targets to include antibodies, antibody-drug conjugates (ADCs) and nucleic acid drugs.
The EMITS facility will conduct research on injectable drug formulation and drug delivery systems. In particular, Eisai plans to explore liposomal and lipid nanoparticle formulations.
Eisai plans to use AI to enhance drug formulation.
It also aims to manufacture investigational injectable drugs at the facility for clinical trials and develop rapid microbial testing methods for microbiological control and ste…